[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201891022A1 - Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела - Google Patents

Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела

Info

Publication number
EA201891022A1
EA201891022A1 EA201891022A EA201891022A EA201891022A1 EA 201891022 A1 EA201891022 A1 EA 201891022A1 EA 201891022 A EA201891022 A EA 201891022A EA 201891022 A EA201891022 A EA 201891022A EA 201891022 A1 EA201891022 A1 EA 201891022A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
framed
tcr complex
virus coding
replicating
Prior art date
Application number
EA201891022A
Other languages
English (en)
Inventor
Элис Клэр Ноэль Бромли
Брайан Роберт Чемпион
Original Assignee
Псайоксус Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522334.0A external-priority patent/GB201522334D0/en
Priority claimed from GBGB1607463.5A external-priority patent/GB201607463D0/en
Priority claimed from GBGB1617206.6A external-priority patent/GB201617206D0/en
Priority claimed from GBGB1617207.4A external-priority patent/GB201617207D0/en
Application filed by Псайоксус Терапьютикс Лимитед filed Critical Псайоксус Терапьютикс Лимитед
Publication of EA201891022A1 publication Critical patent/EA201891022A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В рамках настоящего изобретения предложен не способный реплицироваться онколитический вирусный вектор или способный реплицироваться онколитический вирус, кодирующий антитело к антигенспецифическому комплексу T-клеточного рецептора (TCR) или связывающий фрагмент указанного антитела для экспрессии на поверхности раковой клетки, содержащие их фармацевтические композиции и применение любого указанного выше для лечения, в частности для лечения рака.
EA201891022A 2015-12-17 2016-12-19 Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела EA201891022A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1522334.0A GB201522334D0 (en) 2015-12-17 2015-12-17 Method
GBGB1607463.5A GB201607463D0 (en) 2016-04-29 2016-04-29 Method
GBGB1617206.6A GB201617206D0 (en) 2016-10-10 2016-10-10 Method
GBGB1617207.4A GB201617207D0 (en) 2016-10-10 2016-10-10 Method
PCT/EP2016/081818 WO2017103291A1 (en) 2015-12-17 2016-12-19 Virus encoding an anti-tcr-complex antibody or fragment

Publications (1)

Publication Number Publication Date
EA201891022A1 true EA201891022A1 (ru) 2019-01-31

Family

ID=57794239

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201891022A EA201891022A1 (ru) 2015-12-17 2016-12-19 Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
EA201891021A EA201891021A1 (ru) 2015-12-17 2016-12-19 Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201891021A EA201891021A1 (ru) 2015-12-17 2016-12-19 Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела

Country Status (19)

Country Link
US (3) US11155622B2 (ru)
EP (2) EP3389683B8 (ru)
JP (2) JP7064437B2 (ru)
KR (2) KR20180108590A (ru)
CN (2) CN108697746A (ru)
AU (2) AU2016372576A1 (ru)
BR (2) BR112018012179A2 (ru)
CA (1) CA3006859A1 (ru)
CL (1) CL2018001611A1 (ru)
CO (1) CO2018005945A2 (ru)
DK (1) DK3389682T3 (ru)
EA (2) EA201891022A1 (ru)
IL (2) IL260027B (ru)
MX (1) MX2018007249A (ru)
MY (1) MY193281A (ru)
PH (1) PH12018501291A1 (ru)
SG (2) SG11201805136TA (ru)
WO (2) WO2017103291A1 (ru)
ZA (1) ZA201803523B (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57043B1 (sr) 2013-10-25 2018-05-31 Psioxus Therapeutics Ltd Onkolitički adenovirusi snabdeveni heterologus genima
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7
MA43163A (fr) 2015-11-02 2018-09-12 Five Prime Therapeutics Inc Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
BR112018012179A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd adenovírus de grupo b que codifica um anticorpo ou fragmento de complexo anti-tcr
AU2017222686B2 (en) 2016-02-25 2021-12-23 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
CA3034517A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
KR20200042904A (ko) * 2017-07-26 2020-04-24 온코루스, 인크. 종양용해성 바이러스 벡터 및 그의 용도
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
CN111989397A (zh) * 2018-03-30 2020-11-24 藤堂具纪 肿胀发生抑制型溶瘤病毒
CA3103374A1 (en) * 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
WO2020050630A1 (ko) 2018-09-07 2020-03-12 주식회사 케이티 비면허 대역에서 무선 통신을 수행하는 방법 및 장치
US20200215133A1 (en) * 2019-01-07 2020-07-09 Sichuan Oncocare Biopharmaceutical, Inc. Combination of immuno-oncolytic virus drugs for enhancing systemic immune response and application thereof
WO2020143221A1 (zh) * 2019-01-07 2020-07-16 四川安可康生物医药有限公司 增强系统免疫应答的免疫溶瘤病毒组合药物及其应用
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
WO2021046653A1 (en) * 2019-09-13 2021-03-18 Centre For Drug Research And Development Anti-oncolytic virus antigen antibodies and methods of using same
CN114729305A (zh) * 2019-10-17 2022-07-08 苏州丹罗医药有限公司 用于免疫治疗的嵌合抗原受体、制备方法及其应用
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN116249559A (zh) * 2020-08-31 2023-06-09 埃克苏马生物技术公司 抗独特型组合物及其使用方法
WO2022158844A1 (ko) * 2021-01-19 2022-07-28 광주과학기술원 Igsf4의 막 관통 도메인을 발현하는 t 세포 및 이의 이용
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CN113355296A (zh) * 2021-06-07 2021-09-07 中国人民解放军空军军医大学 一种表达人ccl19的重组溶瘤新城疫病毒及其应用
IL313740A (en) 2021-12-23 2024-08-01 Helsingin Yliopisto A method for screening a signal peptide for efficient expression and secretion of a heterologous polypeptide in mammalian cells
CN114891126B (zh) * 2022-06-23 2023-05-09 上海安库生医生物科技有限公司 一种靶向fshr和cd3分子的双结合蛋白及其应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
DE69838510T2 (de) 1997-02-20 2008-07-03 Johns Hopkins University School Of Medicine Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren
DE69838340T2 (de) 1997-10-09 2008-05-21 Wellstat Biologics Corp. Behandlung von neoplasmen mit interferonempfindlichen, klonalen viren
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
EP1112372A1 (en) 1998-09-11 2001-07-04 Genvec, Inc. Alternatively targeted adenovirus
ES2286902T3 (es) 1998-12-09 2007-12-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Vector recombinante que expresa multiples moleculas coestimulantes y aplicaciones de las mismas.
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
BR0009595A (pt) 1999-04-09 2001-12-26 Aventis Pharma Sa Composição lìquida ou congelada e utilizaçãoterapêutica ou profilática da mesma
DK1054064T4 (da) 1999-05-17 2010-05-03 Crucell Holland Bv Vehikler til adenovirus afledt genafgivelse omfattende mindst et element af adenovirus type 35
JP2003501041A (ja) 1999-06-01 2003-01-14 ユニバーシティ オブ ワシントン 細胞特異的な感染およびゲノム組み込みのためのキメラファイバータンパク質を発現する組換えアデノウイルスベクター
ES2478635T3 (es) 1999-08-09 2014-07-22 Targeted Genetics Corporation Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
JP4921669B2 (ja) 2000-01-21 2012-04-25 バイオヴェックス リミテッド ウイルス株
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP2003534806A (ja) 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
ATE385504T1 (de) 2000-06-06 2008-02-15 Bristol Myers Squibb Co Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
EP1470233A1 (en) 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en) 2003-03-28 2004-10-14 Saint Louis University Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CN1934253A (zh) 2003-07-18 2007-03-21 昂尼克斯药物公司 用于治疗疾病的b亚组腺病毒载体
AU2004283850C1 (en) 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
BRPI0510475B8 (pt) 2004-05-26 2021-05-25 Bayer Pharma AG adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
WO2006039045A2 (en) 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
EP1929021A2 (en) 2005-08-31 2008-06-11 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
JP2008050051A (ja) 2006-08-28 2008-03-06 Bokuson Uesuto:Kk ディスペンスヘッド
US8216819B2 (en) 2006-12-22 2012-07-10 Psioxus Therapeutics Limited Generation of oncolytic adenoviruses and uses thereof
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
WO2009143610A1 (en) 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
ES2604309T3 (es) 2008-10-01 2017-03-06 Amgen Research (Munich) Gmbh Anticuerpo biespecífico de cadena sencilla PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinaxCD3, EpCAMxCD3, IGF-1RxCD3 o FAPALPHA xCD3 específico entre especies
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP2486137B1 (en) 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors
AU2011292120B2 (en) 2010-08-16 2015-07-30 Salk Institute For Biological Studies Adenoviral assembly method
AU2011306845C1 (en) 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies
AU2012298537B2 (en) 2011-08-23 2017-08-10 Roche Glycart Ag Bispecific T cell activating antigen binding molecules
EP2780020A4 (en) 2011-11-14 2016-03-02 Regenerative Sciences Llc SUSPENDED PARTICLE DISTRIBUTION SYSTEMS AND METHODS
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
RU2609651C2 (ru) 2012-05-04 2017-02-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
EP2964241A1 (en) * 2013-03-05 2016-01-13 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
RS57043B1 (sr) 2013-10-25 2018-05-31 Psioxus Therapeutics Ltd Onkolitički adenovirusi snabdeveni heterologus genima
SG10201907841UA (en) 2013-11-22 2019-10-30 Dnatrix Inc Adenovirus expressing immune cell stimulatory receptor agonist(s)
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
SG11201701502VA (en) 2014-08-27 2017-03-30 Psioxus Therapeutics Ltd A process for the production of adenovirus
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
WO2016146894A1 (en) 2015-03-17 2016-09-22 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7
BR112018012179A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd adenovírus de grupo b que codifica um anticorpo ou fragmento de complexo anti-tcr
WO2017161360A2 (en) 2016-03-18 2017-09-21 Nant Holdings Ip, Llc Multimodal vector for dendritic cell infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3034517A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell activator
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
KR20180107105A (ko) 2018-10-01
EA201891021A1 (ru) 2018-11-30
US20190077865A1 (en) 2019-03-14
EP3389683B1 (en) 2023-03-29
US11970536B2 (en) 2024-04-30
US11155622B2 (en) 2021-10-26
AU2016369485B2 (en) 2024-02-01
JP2019508017A (ja) 2019-03-28
ZA201803523B (en) 2022-07-27
CL2018001611A1 (es) 2018-09-14
WO2017103290A1 (en) 2017-06-22
SG11201805137XA (en) 2018-07-30
EP3389682B1 (en) 2021-11-17
JP7064437B2 (ja) 2022-05-10
SG11201805136TA (en) 2018-07-30
EP3389682A1 (en) 2018-10-24
BR112018012180A2 (pt) 2018-12-04
MY193281A (en) 2022-09-30
CO2018005945A2 (es) 2018-08-21
AU2016372576A1 (en) 2018-06-21
US20240247061A1 (en) 2024-07-25
EP3389683A1 (en) 2018-10-24
EP3389683B8 (en) 2023-05-03
BR112018012179A2 (pt) 2018-12-04
IL260033A (en) 2018-07-31
PH12018501291A1 (en) 2019-02-18
CA3006859A1 (en) 2017-06-22
WO2017103291A1 (en) 2017-06-22
DK3389682T3 (da) 2022-01-24
AU2016369485A1 (en) 2018-06-21
JP2019502379A (ja) 2019-01-31
US20180369304A1 (en) 2018-12-27
IL260027B (en) 2022-07-01
CN108697745A (zh) 2018-10-23
CN108697746A (zh) 2018-10-23
KR20180108590A (ko) 2018-10-04
MX2018007249A (es) 2019-05-16
IL260027A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
EA201891022A1 (ru) Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CL2016000734A1 (es) Receptor de antigeno quimerico
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
UY36538A (es) Anticuerpos humanos contra la glicoproteína del virus del ébola
BR112019002687A2 (pt) receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MX2019008346A (es) Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2021000435A (es) Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
MY195115A (en) Antibodies targeting g-protein coupled receptor and methods of use
PE20171133A1 (es) Particulas tipo virus modificadas de cmv
UY35965A (es) Anticuerpos humanos contra pd?l1
EA202192165A1 (ru) Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
DK3160476T3 (da) Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
AR101997A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
DK3172233T3 (da) Anti-cd74-antistoffer, sammensætninger omfattende anti-cd74- antistoffer og fremgangsmåder til anvendelse af anti-cd74-antistoffer
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CO2017011529A2 (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable (fcrn)
CR20170518A (es) Neutralización del virus chikungunya mediada por anticuerpos.
EA202091844A1 (ru) Композиции аденоассоциированных вирусов для переноса гена pah и способы их применения
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop